GlassScriptPhysician profile
Pietro Cavataio
NPI 1134195258
$11,209.15
in general payments reported to CMS, 2019-2025
57 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $1,382 · 2021: $1,955 · 2022: $1,435 · 2023: $1,033 · 2024: $1,729 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,814.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,891.15 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,067.82 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $987.59 | 2019-2022 | |
| Lilly USA, LLC | $831.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $698.09 | 2019-2025 | |
| Novo Nordisk INC | $591.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $430.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $419.46 | 2019-2020 | |
| Glaxosmithkline, LLC. | $410.62 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.86 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Teva Pharmaceuticals USA, INC. | $282.75 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $205.12 | 2021-2025 | Qelbree, Qelbree, Tlando |
| Otsuka America Pharmaceutical, INC. | $193.47 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $186.02 | 2019-2022 | |
| Amarin Pharma, INC. | $180.94 | 2020-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pietro Cavataio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.